At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
04 11 2020
Historique:
received: 14 07 2020
accepted: 08 10 2020
entrez: 4 11 2020
pubmed: 5 11 2020
medline: 18 11 2020
Statut: epublish

Résumé

Tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral ribonucleic acid (RNA) using reverse transcription polymerase chain reaction (RT-PCR) are pivotal to detecting current coronavirus disease (COVID-19) and duration of detectable virus indicating potential for infectivity. We conducted an individual participant data (IPD) systematic review of longitudinal studies of RT-PCR test results in symptomatic SARS-CoV-2. We searched PubMed, LitCOVID, medRxiv, and COVID-19 Living Evidence databases. We assessed risk of bias using a QUADAS-2 adaptation. Outcomes were the percentage of positive test results by time and the duration of detectable virus, by anatomical sampling sites. Of 5078 studies screened, we included 32 studies with 1023 SARS-CoV-2 infected participants and 1619 test results, from - 6 to 66 days post-symptom onset and hospitalisation. The highest percentage virus detection was from nasopharyngeal sampling between 0 and 4 days post-symptom onset at 89% (95% confidence interval (CI) 83 to 93) dropping to 54% (95% CI 47 to 61) after 10 to 14 days. On average, duration of detectable virus was longer with lower respiratory tract (LRT) sampling than upper respiratory tract (URT). Duration of faecal and respiratory tract virus detection varied greatly within individual participants. In some participants, virus was still detectable at 46 days post-symptom onset. RT-PCR misses detection of people with SARS-CoV-2 infection; early sampling minimises false negative diagnoses. Beyond 10 days post-symptom onset, lower RT or faecal testing may be preferred sampling sites. The included studies are open to substantial risk of bias, so the positivity rates are probably overestimated.

Sections du résumé

BACKGROUND
Tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral ribonucleic acid (RNA) using reverse transcription polymerase chain reaction (RT-PCR) are pivotal to detecting current coronavirus disease (COVID-19) and duration of detectable virus indicating potential for infectivity.
METHODS
We conducted an individual participant data (IPD) systematic review of longitudinal studies of RT-PCR test results in symptomatic SARS-CoV-2. We searched PubMed, LitCOVID, medRxiv, and COVID-19 Living Evidence databases. We assessed risk of bias using a QUADAS-2 adaptation. Outcomes were the percentage of positive test results by time and the duration of detectable virus, by anatomical sampling sites.
RESULTS
Of 5078 studies screened, we included 32 studies with 1023 SARS-CoV-2 infected participants and 1619 test results, from - 6 to 66 days post-symptom onset and hospitalisation. The highest percentage virus detection was from nasopharyngeal sampling between 0 and 4 days post-symptom onset at 89% (95% confidence interval (CI) 83 to 93) dropping to 54% (95% CI 47 to 61) after 10 to 14 days. On average, duration of detectable virus was longer with lower respiratory tract (LRT) sampling than upper respiratory tract (URT). Duration of faecal and respiratory tract virus detection varied greatly within individual participants. In some participants, virus was still detectable at 46 days post-symptom onset.
CONCLUSIONS
RT-PCR misses detection of people with SARS-CoV-2 infection; early sampling minimises false negative diagnoses. Beyond 10 days post-symptom onset, lower RT or faecal testing may be preferred sampling sites. The included studies are open to substantial risk of bias, so the positivity rates are probably overestimated.

Identifiants

pubmed: 33143712
doi: 10.1186/s12916-020-01810-8
pii: 10.1186/s12916-020-01810-8
pmc: PMC7609379
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

346

Références

Lancet Gastroenterol Hepatol. 2020 May;5(5):434-435
pubmed: 32199469
Int J Infect Dis. 2020 May;94:68-71
pubmed: 32179140
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Emerg Infect Dis. 2020 Jun;26(6):1343-1345
pubmed: 32163030
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Emerg Microbes Infect. 2020 Dec;9(1):386-389
pubmed: 32065057
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Euro Surveill. 2020 Dec;25(50):
pubmed: 33334398
Clin Infect Dis. 2021 Nov 2;73(9):e3106-e3109
pubmed: 33075138
Clin Infect Dis. 2020 Nov 19;71(16):2249-2251
pubmed: 32306036
Clin Infect Dis. 2020 Jul 28;71(15):793-798
pubmed: 32221523
Nat Med. 2020 Jun;26(6):861-868
pubmed: 32327757
J Med Virol. 2020 Jun;92(6):589-594
pubmed: 32100876
Clin Infect Dis. 2020 Sep 12;71(6):1547-1551
pubmed: 32112072
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
J Med Virol. 2020 Sep;92(9):1641-1648
pubmed: 32227494
J Infect. 2020 Aug;81(2):e49-e52
pubmed: 32335176
J Infect. 2020 May;80(5):e1-e6
pubmed: 32171869
Int J Infect Dis. 2020 Jun;95:363-370
pubmed: 32335340
Ann Intern Med. 2020 Jun 16;172(12):832-834
pubmed: 32227141
Int J Biol Sci. 2020 Mar 15;16(10):1698-1707
pubmed: 32226287
Int J Infect Dis. 2020 Jun;95:183-191
pubmed: 32173576
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Clin Infect Dis. 2020 Jul 28;71(15):799-806
pubmed: 32271376
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
JAMA. 2015 Apr 28;313(16):1657-65
pubmed: 25919529
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Am J Respir Crit Care Med. 2020 May 1;201(9):1150-1152
pubmed: 32200654
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613
Emerg Infect Dis. 2020 Jul;26(7):1626-1628
pubmed: 32228809

Auteurs

Sue Mallett (S)

Centre for Medical Imaging, University College London, 2nd Floor, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK. sue.mallett@ucl.ac.uk.

A Joy Allen (AJ)

NIHR In Vitro Diagnostics Co-operative, Newcastle University, Newcastle upon Tyne, NE2 7RU, UK.

Sara Graziadio (S)

NIHR In Vitro Diagnostics Co-operative, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK.

Stuart A Taylor (SA)

Centre for Medical Imaging, University College London, 2nd Floor, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.

Naomi S Sakai (NS)

Centre for Medical Imaging, University College London, 2nd Floor, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.

Kile Green (K)

NIHR In Vitro Diagnostics Co-operative, Newcastle University, Newcastle upon Tyne, NE2 7RU, UK.

Jana Suklan (J)

NIHR In Vitro Diagnostics Co-operative, Newcastle University, Newcastle upon Tyne, NE2 7RU, UK.

Chris Hyde (C)

Exeter Test Group, Institute of Health Research, University of Exeter Medical School, University of Exeter, College House, St Luke's Campus, Exeter, EX1 2LU, UK.

Bethany Shinkins (B)

Test Evaluation Group, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Worsley Building , Clarendon Way, Leeds, LS2 9LJ, UK.

Zhivko Zhelev (Z)

Exeter Test Group, Institute of Health Research, University of Exeter Medical School, University of Exeter, College House, St Luke's Campus, Exeter, EX1 2LU, UK.

Jaime Peters (J)

Exeter Test Group, Institute of Health Research, University of Exeter Medical School, University of Exeter, College House, St Luke's Campus, Exeter, EX1 2LU, UK.

Philip J Turner (PJ)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Nia W Roberts (NW)

Cancer Services, Gastroenterology, Population Health & Primary Care, Bodleian Health Care Libraries, University of Oxford, Oxford, OX2 6HT, UK.

Lavinia Ferrante di Ruffano (LF)

Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.

Robert Wolff (R)

Kleijnen Systematic Reviews Ltd, York, UK.

Penny Whiting (P)

Bristol Medical School, University of Bristol, Bristol, UK.

Amanda Winter (A)

NIHR In Vitro Diagnostics Co-operative, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK.

Gauraang Bhatnagar (G)

Frimley Health NHS Foundation Trust, Frimley, Camberley, GU16 7UJ, UK.

Brian D Nicholson (BD)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Steve Halligan (S)

Centre for Medical Imaging, University College London, 2nd Floor, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH